Vanessa Malier (L) and Rémi Droller, managing partners at Kurma Partners

Kur­ma scores $175M in first clos­ing of biotech/healthtech fund — the VC's largest yet

French VC Kur­ma has been in­vest­ing in­to sev­er­al com­pa­nies re­cent­ly, such as AR­M­GO Phar­ma and Emer­gence Ther­a­peu­tics. With its new biotech and healthtech-fo­cused fund, the VC is now look­ing to ex­pand its of­fer­ings in pos­si­bly its biggest fund to date.

The VC said this morn­ing that the fund, dubbed the Growth Op­por­tu­ni­ties Fund, hit its first clos­ing, se­cur­ing just shy of $175 mil­lion from dif­fer­ent in­vestors. But the firm has a high­er goal: €250 mil­lion, or $273 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.